SEGMENTED INFORMATION (Tables)

3 Months Ended

Mar. 31, 2022

SEGMENTED INFORMATION

Schedule of segmented revenue and net profit/(loss)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2022
REVENUE	$	24,269		$	3,004,676		$	-		$	3,028,945
COST OF REVENUE		(30,832	)		(2,664,574	)		-			(2,695,406	)
GROSS (LOSS)/PROFIT		(6,563	)		340,102			-			333,539
OTHER INCOME		2,076			44,306			12			46,394
OPERATING EXPENSES
General and administrative		(21,248	)		(297,769	)		(26,225	)		(345,242	)
FINANCE COSTS		(799	)		(2,527	)		-			(3,326	)
(LOSS)/PROFIT BEFORE TAX		(26,534	)		84,112			(26,213	)		31,365
Tax expense		-			(14,299	)		-			(14,299	)
NET (LOSS)/PROFIT	$	(26,534	)	$	69,813		$	(26,213	)	$	17,066

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2021
REVENUE	$	97,363		$	3,351,796		$	-		$	3,449,159
COST OF REVENUE		(67,707	)		(2,798,887	)		-			(2,866,594	)
GROSS PROFIT		29,656			552,909			-			582,565
OTHER INCOME		763			61,625			-			62,388
OPERATING EXPENSES
General and administrative		(22,511	)		(233,152	)		(47,188	)		(302,851	)
FINANCE COSTS		(1,207	)		(2,151	)		-			(3,358	)
PROFIT/(LOSS) BEFORE TAX		6,701			379,231			(47,188	)		338,744
Tax expense		-			-			-			-
NET PROFIT/(LOSS)	$	6,701		$	379,231		$	(47,188	)	$	338,744

	As of March 31, 2022 and December 31, 2021
	Total Assets				Total Liabilities
	2022		2021		2022		2021
BGLC & Bionexus	$	1,109,804	$	1,167,214	$	125,696	$	121,586
Chemrex		8,065,618		8,407,176		1,921,657		2,273,025
TOTAL		9,175,422		9,574,390		2,047,353		2,394,611